BRENTUXIMAB VEDOTIN | B125388 | SEATTLE GENETICS
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 7-Year Orphan | Nov. 10, 2029 | Active | Purple Book |
| 12-Year BPCIA | Aug. 19, 2023 | Expired | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12364767(composition) · relevance 90/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 176 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Seagen Inc. v. Daiichi Sankyo Co., Ltd. 1 patentAntibody-drug conjugate (ADC) - DS-8201 with trastuzumab antibody and camptothecin derivative DXd | E.D. Tex. | 2020-10-19 | Terminated 2022-07-19 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.